Rosen Law Firm Investigates ADMA Biologics for Securities Class Action Claims
On May 12, 2026, the renowned Rosen Law Firm announced that it is actively investigating possible securities class action claims concerning ADMA Biologics, Inc. (NASDAQ: ADMA). This investigation comes in light of allegations suggesting that the company might have disseminated materially misleading business information to its investors. This investigation emerges from growing concerns regarding ADMA Biologics, especially after a significant drop in its stock price.
The catalyst for this investigation was a report released by short-seller Culper Research on March 24, 2026, which accused ADMA of engaging in practices known as "channel stuffing"> to artificially inflate its revenue figures. Following the revelations contained in this report, ADMA Biologics experienced a staggering 16.6% drop in its stock price. For investors who purchased shares of ADMA Biologics and have suffered losses, this may be an opportunity for them to seek compensation without incurring out-of-pocket costs through a contingency fee arrangement.
Rosen Law Firm emphasizes the importance for affected shareholders to come forward and explore their legal options. Typically, emerging from such investigations, class action lawsuits can help recover investor losses. Interested investors are encouraged to associate with experienced legal counsel well-versed in handling securities class actions. The Rosen Law Firm has a strong track record of success and is recognized for its advocacy on behalf of investors in various notably large cases. Notably, the firm has been recognized as having achieved the largest class action settlement against a Chinese entity and continues to hold a leading position in the securities litigation arena.
The firm encourages investors impacted by the alleged misleading practices of ADMA Biologics to take the next steps. For those interested in joining the potential class action, they can do so via the firm’s dedicated web portal or by reaching out directly to attorney Phillip Kim at the provided contact details. Rosen Law Firm stands out for its remarkable history, with hundreds of millions of dollars recovered for investors in recent years, showcasing its capability and determination in the realm of securities litigation. The firm aims to provide clarity and support for those who find themselves entangled in financial misrepresentations by companies they trusted.
As litigation regarding ADMA Biologics progresses, updates will be provided through the firm’s various social media platforms. Investors are urged to stay informed regarding developments, which could prove to be crucial in their pursuit of justice. Attorney advertising serves to inform potential clients of the firm’s success in not just representing investors but also in making substantive recoveries.
For shareholders involved, now may be the opportune moment to evaluate their legal rights and take action toward compensation for potential losses incurred due to misleading corporate communications from ADMA Biologics. With a determined law firm like Rosen Law Firm leading the charge, there exists optimism for a pathway to recovery for those affected by these challenging circumstances.
The catalyst for this investigation was a report released by short-seller Culper Research on March 24, 2026, which accused ADMA of engaging in practices known as "channel stuffing"> to artificially inflate its revenue figures. Following the revelations contained in this report, ADMA Biologics experienced a staggering 16.6% drop in its stock price. For investors who purchased shares of ADMA Biologics and have suffered losses, this may be an opportunity for them to seek compensation without incurring out-of-pocket costs through a contingency fee arrangement.
Rosen Law Firm emphasizes the importance for affected shareholders to come forward and explore their legal options. Typically, emerging from such investigations, class action lawsuits can help recover investor losses. Interested investors are encouraged to associate with experienced legal counsel well-versed in handling securities class actions. The Rosen Law Firm has a strong track record of success and is recognized for its advocacy on behalf of investors in various notably large cases. Notably, the firm has been recognized as having achieved the largest class action settlement against a Chinese entity and continues to hold a leading position in the securities litigation arena.
The firm encourages investors impacted by the alleged misleading practices of ADMA Biologics to take the next steps. For those interested in joining the potential class action, they can do so via the firm’s dedicated web portal or by reaching out directly to attorney Phillip Kim at the provided contact details. Rosen Law Firm stands out for its remarkable history, with hundreds of millions of dollars recovered for investors in recent years, showcasing its capability and determination in the realm of securities litigation. The firm aims to provide clarity and support for those who find themselves entangled in financial misrepresentations by companies they trusted.
As litigation regarding ADMA Biologics progresses, updates will be provided through the firm’s various social media platforms. Investors are urged to stay informed regarding developments, which could prove to be crucial in their pursuit of justice. Attorney advertising serves to inform potential clients of the firm’s success in not just representing investors but also in making substantive recoveries.
For shareholders involved, now may be the opportune moment to evaluate their legal rights and take action toward compensation for potential losses incurred due to misleading corporate communications from ADMA Biologics. With a determined law firm like Rosen Law Firm leading the charge, there exists optimism for a pathway to recovery for those affected by these challenging circumstances.
Topics General Business）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.